4basebio announces lease of an innovation hub and manufacturing facility in Cambridge, UK
Posted:
4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansion into a new innovation hub and manufacturing facility in Cambridge, UK, supporting growing demand for research and high-quality grade manufacturing of synthetic DNA for gene and cell therapies, mRNA vaccines, genome editing, or DNA vaccines.
Healthcare innovation continues to evolve at an extraordinary pace — driven by advances in AI, digital health, virtual care, and new models of medical education.
At the centre of many of these conversations is Prof. Shafi Ahmed, our Chairman and…
Owkin and Sanofi are expanding their artificial intelligence collaboration through a multi-year agreement to co-develop AI-enabled biopharma agents for drug research and development.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us